Has the management provided any guidance for Q3 or fiscal year 2025 earnings and cash flow outlook?

Answer

Based on the information contained in the Hinge Health second‑quarter 2025 earnings release (the only details provided in the news excerpt), management did not disclose any guidance for either:

• Q3 2025 (the next quarter), or
  
• The full fiscal‑year 2025 outlook for earnings and cash‑flow.

The release focuses solely on the Q2 results—highlighting a 55 % year‑over‑year revenue increase and a “strong free cash‑flow margin”—and includes a CEO quote about the momentum of the AI‑powered platform. No forward‑looking statements, forecasts, or guidance ranges for subsequent quarters or the remainder of the fiscal year are mentioned.

What this means for investors or analysts

• No quantitative targets are available at this time for Q3 or FY2025, so any projections would need to rely on external analysis (e.g., historical growth rates, management commentary from other calls, or comparable company trends).
  
• Future updates: Keep an eye on Hinge Health’s next earnings release (typically for Q3) or any investor‑relations webcast/press release where the company may issue guidance.
  
• Potential follow‑up: If you need guidance for planning or valuation, you may consider reaching out directly to Hinge Health’s investor‑relations team or monitoring subsequent SEC filings (e.g., Form 8‑K) that sometimes contain forward‑looking guidance after a quarter’s results are reported.

In short, the current Q2 2025 announcement does not provide any guidance for Q3 2025 or the full fiscal‑year 2025 earnings or cash‑flow outlook.